Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Your missing the point! It really makes no difference what the small cost of the drug is. If you need 100 small bioreactors instead of one or 5 large ones, WHAT DIFFERENCE DOES IT MAKE?
The cides work and prevent suffering and death! The scale of the plant is immaterial.
NanoViricides Reports That It Has Shipped anti-Ebola Drug Candidates For Testing to a BSL-4 Hi-Security Biocontainment Laboratory
PR Newswire
WEST HAVEN, Conn., Jan. 22, 2015
WEST HAVEN, Conn., Jan. 22, 2015 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), a nanomedicine company developing anti-viral drugs, reported that it has shipped several anti-Ebola nanoviricide® drug candidates to a hi-security bio-containment facility in the US that is capable of performing evaluation of these drug candidates in the required biological safety level 4 (BSL-4) environment.
Targeted Virus-Killing Nanomedicines
The Company has designed these novel anti-Ebola broad-spectrum drug candidates such that they are expected to continue to work in spite of mutations in the field.
Using NanoViricides's rapid design platform, it took only 4 months from design to synthesis of the multiple drug candidates. These candidates are designed to attack the Ebola virus at the site on the virus that does not change in spite of mutations because the virus uses this site to bind to its cognate receptor in human cells, namely NPC1. Some of the candidates are designed to attack another conserved site on the Ebola virus that is thought to be involved in the fusion process of the virus required for it to successfully enter the cell.
The Company already has the capability of producing sufficient quantities of a successful anti-Ebola drug in its new cGMP-capable facility in Shelton, CT, for combating the current Ebola epidemic. This pilot scale manufacturing facility will be able to supply the successful nanoviricides drug candidate in quantities needed for the treatment of patients in West Africa infected with the Ebola virus. NanoViricides, Inc. is one of the very few companies that has the ability produce its drug candidates at this full-response scale.
The Company had previously developed anti-Ebola drug candidates that demonstrated the validity and potential of the Company's approach, based on cell culture and animal testing conducted at USAMRIID in 2008-2009. At that time, the cognate receptor of the Ebola virus was still unknown and the Company used certain heuristic approaches to design potential drug candidates for the purpose of validating our approach. The Company had to de-prioritize this development in order to focus on the development of its lead drug candidate, Injectable FluCide™, for treatment of hospitalized patients with influenza. The current outbreak in Africa has unequivocally demonstrated the need for an effective, broad-spectrum, anti-Ebola therapeutic. NanoViricides engaged into the anti-Ebola drug development with the highest priority in order to respond to this challenge recently.
About NanoViricides: "
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
I would have preferred a cash stock buy back if they had to use some cash. Instead they made only $6,000,000 on this transaction.
NANOVIRICIDES, INC.
Control# 7 yOURS
2015 Annual Meeting of Shareholders
Friday, January 23, 2015
For holders as of: Friday, November 28, 2014
Cusip: 63-203
Thank you for voting!
have you voted your shares? Do it to show how you care. A vote of confidence will be appericated.
bOTH numbers are for my yahoo link.
Share Statistics
Avg Vol (3 month)3: 177,495
Avg Vol (10 day)3: 148,075
Shares Outstanding5: 57.11M
Float: 35.38M
% Held by Insiders1: 24.46%
% Held by Institutions1: 8.10%
Shares Short (as of Dec 31, 2014)3: 2.70M
Short Ratio (as of Dec 31, 2014)3: 14.90
Short % of Float (as of Dec 31, 2014)3: 6.20%
Shares Short (prior month)3: 3.05M
Shorts are covering! I wonder why? Not really, I think I know why! NNVC has the cure for all cides, well only the key to make the cure for ALL cides to cure any virus.
Top Institutional Holders
Holder
Shares
% Out
Value*
Reported
Vanguard Group, Inc. (The) 1,081,082 1.85 3,243,246 Sep 30, 2014
BlackRock Fund Advisors 947,390 1.62 2,842,170 Sep 30, 2014
Northern Trust Corporation 425,932 0.73 1,277,796 Sep 30, 2014
State Street Corporation 382,527 0.66 1,147,581 Sep 30, 2014
BlackRock Institutional Trust Company, N.A. 363,725 0.62 1,091,175 Sep 30, 2014
Geode Capital Management, LLC 204,531 0.35 613,593 Sep 30, 2014
Bank of New York Mellon Corporation 172,711 0.30 518,133 Sep 30, 2014
TIAA-CREF Investment Management, LLC 149,200 0.26 447,600 Sep 30, 2014
Bridgeway Capital Management, Inc. 143,000 0.25 429,000 Sep 30, 2014
Goldman Sachs Group, Inc. 130,931 0.22 392,793 Sep 30, 2014
Top Mutual Fund Holders
Holder
Shares
% Out
Value*
Reported
iShares Russell 2000 ETF 639,837 1.10 2,047,478 Nov 30, 2014
Vanguard Total Stock Market Index Fund 635,591 1.09 1,906,773 Sep 30, 2014
Vanguard Extended Market Index Fund 344,847 0.59 1,034,541 Sep 30, 2014
iShares Russell 2000 Growth ETF 286,682 0.49 917,382 Nov 30, 2014
Spartan Extended Market Index Fund 143,363 0.25 458,761 Nov 30, 2014
College Retirement Equities Fund-Stock Account 120,437 0.21 509,448 Jun 30, 2014
iShares Micro Cap ETF 100,645 0.17 322,064 Nov 30, 2014
Bridgeway Funds Inc-Ultra Small Company Market Fund 100,000 0.17 300,000 Sep 30, 2014
Schwab Capital Trust-Small Cap Index Fund 58,800 0.10 238,728 Jul 31, 2014
AQR Funds-AQR Small Cap Momentum Fd 57,800 0.10 173,400 Sep 30, 2014
you response to his presentation will be welcomed by many. tia
Some one put in a market order to sell all or none of 22,000+ shares. It might have been a bank who had a customer with a margin call and they raised cash for them by selling his position out.
Recovering nicely now.
Results have been released. 6,000 animals-no toxicity! testing is now underway, moving into small animals. the study had a start point, 12/14 and it has an end point.. coming soon.
UARMIIR has NNVC's cide in their sights. results must follow as the testing progress. and the time frame is short. 21 days to show disease, how many days to cure, IMHO not many.
if you think making money trading stocks is a worthwhile thing I fell VERY sorry for you.
The DRs put a lot of effort into this endeavor. The results are less than 6 months from totally being on the table. Hats off to them for all the work it took to get here.
Your missing the point of NNVC.
To: drkaz who wrote (3567) 12/24/2014 12:14:34 AM
From: Another_Voice_2 of 3568
Good response to the Ebola work. I might add that the other cide(s) submitted to the USARIDD has some life extension response. Although the test animals died, they lived longer than the non treated subjects.
All the talk has been on a pass fail outcome. If my memory serves here the test animals lived 5 days and the cided creatures lived 7 days. What if that number were stretched to 9 days or 11?
The public confidence of the docs is as expected, very cautious. But between the lines their actions scream, we can do it better than anyone, if not this pass then the next! and much quicker with the USARIDD working shoulder to shoulder with us.
BIGK would you please check in and see what that other place is like. NNVC is to valuable to allow the others to win 4 now!
Get ready guys, this is a cut and paste not altered!
NanoViricides, Inc. Real Time Stock Quotes
NNVC
$12.34
*
9.24
298.06%
Get NNVC Alerts
*Real-Time - data as of 12/4/2014 - Find a broker to begin trading NNVC now
Read more: http://www.nasdaq.com/symbol/nnvc/real-time#ixzz3LAldD6KI
I am an early adopter, I admit it! I have lost money and made money because of this trait.
My frustration with biotech is their willingness to accept the normal course of action. If you running a company for-profit and the best return on investment it to operate the plans on 2 shifts that is what you do. if you need a 3rd shift instead of building a new plant you put on a 3rd shift. Get it, run a the most cost efficient model.
Biotech is different. Peoples health and lives are at stake! Let just stick to viruses for now. NO CURE FOR VIRUSES has ever been found, and passed FDA rigors!!! Now NNVC claims to have a CURE for VIRUSES!!!
With the results shown so far why hasn't some one with a brain at the FDA spoken up. The number of deaths this year will be as my information has indicated will be between 30,000 and 90,000!!!
Shouldn't the FDA say we need a CZAR to look at this program and see how we can save some of those lives. Dr. Seymour has the responsibility to follow the rules and care for the shareholders investments. It is his job to follow all the guidelines to ensure a profitable product.
At this point in NNVC's cycle it seems to me to be a slam dunk the Flucide is a cure for this virus. As of today the BASi work has reported no bad news, which means ever thing is OK! The CZAR should be pushing to make sure that the goal and be reached as quickly as possible. Data should be analyzed AS QUICKLY AS POSSIBLE!!! 2nd and 3rd shifts, no time off for a weekend. And any tests that can be started before the data is reported begun without hesitation.
Looking back to all the test animals and data should have the CZAR jumping off the desk to get to the finish line.
yes in other biotechs idbe for example
Yep, i did some work on the flight deck of CVA-19. The jet blast will be felt on wall street as NNVC will make the front pages. The short will be blown over board.
We seem to need a discussion about the difference between vaccines and cures.
COO DOOS to Dr. Seymour for getting the word cure into the senate bill. Since our method of treating Ebola is a cure it needs to be in a different category.
Great point Big Hammer. Why ship to BASi and have another round of verifying their work? Why sign with the Army and ship into the inferno of Ebola if the product MIGHT not show some margin of efficacy? Why even try on Ebola, they could have ducked and no one notice? Why spend money on buying a plant, designing it to WORLD CLASS levels, then building it, have it cleaned to the highest standards, and hire new staff to work there? Why hire another accounting firm with experience to look at and report their monetary fiscal responsible methods?
6,000 sacrificed animals... need I say more?
IMHO, what do I know, I am all in and hating that the sp is where it is. even tho I am green, been here so long.
From: AnotherVoice 12/4/2014 7:53:56 AM
of 3122
Enough bike stuff, lets get to the real stuff.
PPS 3+ shares 54MM priority voucher 125mm to 250mm !!! that's $2 to $$4 per share in cash.
Then there is the business side of licenses and revenue.
What are the odds of success? xxx%. you tell me. it looks like north of 95%.
When will the world embrace this company and give the good Dr.s their due respect?
Missing a deadline is different from an INDEPENDANT company conducting safety work.
Flucide... NO NEWS IS GOOD NEWS!!!
Flucide is marching thru the tests at BASi.
me too, the si seems ok.
Peter Piot, one of the scientists who first discovered Ebola in 1976, warned last week that the epidemic could get worse before it gets better. "Let's not forget that this whole epidemic started with one person -- in other words, it will not be over until the last person with Ebola is dead or has recovered without infecting other people. That is the daunting task we face," Piot said.
CDC: More Than 1,400 People in U.S. Being Actively Monitored for Ebola
by sattkisson
on December 1, 2014
in News
1 Comment
Thomas W. Geisbert, Boston University School of Medicine - PLoS Pathogens, November 2008 direct link to the image description page doi:10.1371/journal.ppat.1000225 Color-enhanced electron micrograph of Ebola virus particles.
[Above: Color-enhanced electron micrograph of Ebola virus particles. Courtesy: Thomas W. Geisbert, Boston University School of Medicine.]
The killer virus Ebola may not be front and center in the news, but it’s still in the forefront of efforts by health officials nationwide. As of today, more than 1,400 people in 44 states in the U.S. are being actively monitored by state and local health departments after returning from West Africa. The good news is that no new cases have been reported in the U.S. since Oct. 23.
According to the Centers for Disease Control, which provided the figure,
“They are being monitored because they came from one of the four countries with ongoing Ebola outbreaks.”
Responding to a public outcry, the Department of Homeland Security began, on Oct. 22, requiring all U.S. bound passengers from the primary Ebola-infected West African nations to arrive at one of five U.S. airports with enhanced screening.
To date, ten people have been treated for Ebola in the U.S. since late September.
More than 1,400 people in 44 states in the U.S. are being actively monitored for Ebola–CDC
Patients with Ebola Brought to U.S.
A total of six people have been brought to the U.S. after contracting Ebola in West Africa: five healthcare workers and one photojournalist. The photojournalist is 33-year old Ashoka Mukpo. All but one survived. Dr. Martin Salia, a legal permanent resident of the U.S., was already critically ill when he arrived from Sierra Leone for treatment at Nebraska Medical Center in Omaha. He died just a few days later on Nov. 17. Officials say they don’t know exactly how he contracted the virus.
Ebola Cases Diagnosed in the U.S.
A total of four people have been diagnosed with Ebola in the U.S. since Sept. 30. All of them recovered except one.
September 30, 2014 – CDC confirmed the first laboratory-confirmed case of Ebola to be diagnosed in the United States in Thomas Eric Duncan who had traveled to Dallas, Texas from Liberia. Local public health officials identified all of Duncan’s close contacts for daily monitoring for 21 days after exposure. Duncan died on Oct. 8. By Nov. 7, all of his close contacts had completed the 21-day monitoring period.
October 10, 2014 – Nina Pham, a 26-year old nurse who cared for Duncan at Texas Presbyterian Hospital tested positive for Ebola and was taken to the National Institutes for Health (NIH) Clinical Center. She recovered and was discharged on Oct. 24.
October 15, 2014 – Amber Vinson, a 29-year old nurse, became the second of Duncan’s health care workers to test positive for Ebola and was taken to Emory Hospital in Atlanta, Georgia. She had flown from Dallas to Cleveland on Oct. 10, and from Cleveland to Dallas on Oct. 13. CDC officials say they “worked to ensure that all passengers and crew on the two flights were contacted by public health professionals to answer their questions and arrange follow up as necessary.” The patient recovered and was discharged Oct. 28 and all monitored passengers completed monitoring by Nov. 3.
October 23, 2014 – The New York City Department of Health and Mental Hygiene reported Ebola in Dr. Craig Spencer, a medical aid worker who had returned to New York City from Guinea, where he served with Doctors Without Borders. He recovered and was discharged from Bellevue Hospital Center Nov. 11. No cases developed from outings he’d made in New York prior to being admitted to the hospital with a fever.
PPS is climbing slowly in response to the message. the short interest is down but still way to high for this stock. too much money in the bank to justify the number if shorts. They maybe in a bad position today. But just wait until we ship, and get an update from BASi!
More form the original post.
This dinner was amazing, wish I could have been there.
When I read the original post my thoughts were that each topic would create an amazing amount of post dissecting every nuance of it.
The plant is completed and scale-up continues
A contract with USAMRIID has been signed (What a coup that was)
Ebola will be ready to ship as soon as USAMRIID comes back on line after their annual cleaning of the facility
We created the MERS drug for the British government (remember that disease) in short order and if Ebola hadn’t come along, they would have tested it by now
We’re actively hiring and a group of new scientists are starting this month
All of the TheraCour scientists are under Dr Diwan’s direction so they’re essentially full-time NNVC employees
The lawsuit with Brammel was settled
It’s been a helluva good 14 months
What most people don’t seem to realize is that any other pharma would spend 12-14 years and $2.55B taking a drug to market
We plan to do it in 10 years for $50M
And if they want to do a second drug, they have to start from scratch.
For us, the time for new drug development is measured in weeks, not years
That’s the most amazing thing about the platform technology concept
good job fn
We should take up a collection to cover his dinner. Payable in HI with drinks. I am for one, the first one.
Shorts are starting to bailout.
Settlement Date Short Interest Avg Daily Share Volume Days To Cover 11/14/2014 3,694,998 151,032 24.465001 10/31/2014 3,963,207 262,372 15.105297 10/15/2014 4,061,301 437,513 9.282698 9/30/2014 4,135,101 221,280 18.687188 9/15/2014 3,972,152 170,797 23.256568 8/29/2014 4,058,985 161,313 25.162169 8/15/2014 4,001,090 413,489 9.676412 7/31/2014 4,013,042 252,084 15.919463 7/15/2014 4,213,036 197,335 21.349664
Read more: http://www.nasdaq.com/symbol/nnvc/short-interest#ixzz3KkZZ2OiV
Thanks for taking the time to post this!
15:59:33 $ 3.31
100 15:59:18 $ 3.30
100 15:59:02 $ 3.30
100 15:58:42 $ 3.29
100 15:57:03 $ 3.29
100 15:55:10 $ 3.29
100 15:54:17 $ 3.29 100
Read more: http://www.nasdaq.com/symbol/nnvc/time-sales#ixzz3KDA3unFr
This was a weaker post but it looked a little. One small step a day, then KaBoom!
Thank FN a for this and with this being Thanksgiving...Happy to all.
With a few correction. reread please.
If guidance is missing leading then lawyers get involved. So, by being on the long side they can stay clear.
Lawyers never sue because guidance is wrong on the short side.
Right now EB2 has the POTENTIAL to throw the guidance out the window.
Africa needs EB2 to work. What % of a cure would you like? 100%, me too, but what % would you consider a success? With the recent published facts about hydration extending life a few days or allowing the body to cure itself by giving it more chance to produce more antibodies.IMHO.
When the first patients came to the USA for treatment if was clear to me that good medical practices were very important. This meant IVs and water, as no cure is available. In Africa many are just left untreated and die. ~70%, so EB2 is the ONLY hope at present.
As soon as we ship and the Docs at Ft. Detrick can observe EB2 results all timelines will be forgotten.
EB2 WILL SAVE LIVES, and the protocols will be overridden.
he pps jumped after my post hit the internet!
I should have add this to my older post that FN bought to my mind.
If our Doc's wanted to line their pockets without any risk they could have work for and found grant money base on the previous results on EBcide
old post
Why hasn't NNVC received money to fight Ebola?
1st. We are a for profit company with PLENTY of money to complete to process to show we have a product! Research outfits don't have the cash to pay their people on new projects.
2nd. The frugal way Dr. Diwan works is so streamlined it does not require a wheelbarrow of money to get to a solution.
3rd. We are doing it to prove our backbone works and this will propel Flucide to a very fast spot.
Good morning to all. And I am hoping that we are another day close to stopping people from dying from all viruses!!!!.
drkaz, with a long term triple net lease it would make no difference. Buying the asset reduces the balance line and would be a trade off. Money to get thru the developing would be shorter and some would holler at that.
Health workers spray themselves with chlorine disinfectants after removing the body a woman who died of Ebola virus in the Aberdeen district of Freetown, Sierra Leone. (REUTERS/Josephus Olu-Mammah)
The U.N. Ebola Emergency Response Mission will not fully meet its Dec. 1 target for containing the virus due to escalating numbers of cases in Sierra Leone, Anthony Banbury, the head of UNMEER, said on Monday.
The mission set the goal in September of having 70 percent of Ebola patients under treatment and 70 percent of victims safely buried. That target will be achieved in some areas, Banbury told Reuters, citing progress in Liberia.
ADVERTISEMENT
"We are going to exceed the Dec 1 targets in some areas. But we are almost certainly going to fall short in others. In both those cases, we will adjust to what the circumstances are on the ground," he said in an interview.
The death toll in the worst Ebola epidemic on record has risen to 5,459 out of 15,351 cases identified in eight countries by Nov. 18, the World Health Organization said on Friday. Almost all those cases are in Guinea, Sierra Leone and Liberia.
Banbury said the areas of greatest concern are in rural parts of Sierra Leone as well as the city of Makeni in the center of the country and Port Loko in the northwest and the capital Freetown.
To combat rural cases, health workers need to deploy rapid response units complete with specialists and equipment that can be flown by helicopter to remote villages at the first sign of the disease's spread, he said.
UNMEER was set up to provide coordination, policy and logistics rather than to treat patients. It needs more resources to halt Ebola as quickly as possible but the emphasis now is on allocating existing resources in the smartest way, he said.
"Earlier decisions about the need for rapid construction of large ETU's (Ebola Treatment Centres) were taken in a certain context where that's what made sense .... Those efforts were to a large degree successful. But in the meantime the disease has spread," he said.
He said surveillance to prevent further cross-border spread of Ebola must be also improved, given the transmission from Guinea into Mali, where at least six people have died.
U.S. Brigadier General Frank Tate, deputy commanding general of U.S forces helping Liberia fight Ebola said on Monday there is a dramatic improvement in the country worst-hit by the outbreak.
Just to make a point about raising and trying to miss lead potential investors. What difference does it make as to who owns the plant?
on't you love it when the price starts down in the am. It SEEMS to get fence sitters hope for a lower entry point to pull the trigger. As the slow trigger fingers see the price rise they are mentally committed to buy in. So what is a few dollars more when a 100x move is coming? Buy today, Have Happy Thanksgiving, And watch as the VIRUS cure company start a fantastic journey.
The date of 1/2015 is a next year date from all the stuff about when we will ship EB2 to the USArmy and move to the new lab as soon as the plant is cleaned and certified.